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Abstract: Alzheimer’s disease (AD) is the most devastating neurodegenerative disorder that affects
the aging population worldwide. Endogenous and exogenous factors are involved in triggering
this complex and multifactorial disease, whose hallmark is Amyloid-β (Aβ), formed by cleavage of
amyloid precursor protein by β- and γ-secretase. While there is no definitive cure for AD to date,
many neuroprotective natural products, such as polyphenol and carotenoid compounds, have shown
promising preventive activity, as well as helping in slowing down disease progression. In this article,
we focus on the chemistry as well as structure of carotenoid compounds and their neuroprotective
activity against Aβ aggregation using molecular docking analysis. In addition to examining the most
prevalent anti-amyloidogenic carotenoid lutein, we studied cryptocapsin, astaxanthin, fucoxanthin,
and the apocarotenoid bixin. Our computational structure-based drug design analysis and molecular
docking simulation revealed important interactions between carotenoids and Aβ via hydrogen
bonding and van der Waals interactions, and shows that carotenoids are powerful anti-amyloidogenic
molecules with a potential role in preventing AD, especially since most of them can cross the
blood-brain barrier and are considered nutraceutical compounds. Our studies thus illuminate
mechanistic insights on how carotenoids inhibit Aβ aggregation. The potential role of carotenoids as
novel therapeutic molecules in treating AD and other neurodegenerative disorders are discussed.
Keywords: Alzheimer’s disease; Amyloid-β aggregation; carotenoid; apocarotenoid; biosynthesis;
molecular docking analysis; structure-activity relationship
1. Introduction
The onset of neurodegenerative disease is a consequence of abnormal conformational/structural
changes in proteins [1]. Alterations in the biochemical homeostasis of the nervous system due to metal
deposition, oxidative stress, disturbances in cholinesterase, and amyloid and tau plaque formation are
highly associated with the initiation and progress of neurodegenerative disease [2–11]. In addition,
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the accumulation of misfolded amyloidogenic proteins in the central nervous system (CNS) has been
linked to progressive neurological impairment [5]. AD, Parkinson’s disease (PD), Huntington’s disease
(HD), and amyotrophic lateral sclerosis (ALS) are the most devastating neurodegenerative diseases,
and all of these conditions affect normal behavior [7,8,12]. AD is the most prevalent worldwide with
more than 45 million aging people suffering from this condition today and the number of cases expected
to triple by 2050 [2]. According to the Aβ hypothesis, Aβ peptide is considered the main trigger of AD
pathogenesis due to reduced Aβ clearance [13,14]. In the human brain, Aβ fibrils are considered the
hallmark of AD and are found in the hippocampus and neocortical regions [13]. Drug discovery for
AD faces two major challenges, namely the lack of an animal model which represents all events that
occur in a patient with AD and the absence of a reliable biomarker that enables monitoring of disease
progression [15–18].
Natural products, such as polyphenols, carotenoids, and other compounds, play an important
role in the prevention of neurodegenerative diseases [19–23]. Polyphenols, such as resveratrol,
epigallocatechin gallate (EGCG), and curcumin, constitute a large family of compounds that have
demonstrated neuroprotective activity [6]. The biggest challenges with these compounds are their
stability and bioavailability. However, structural modification of polyphenols has been demonstrated
to improve their biological activity [24].
Carotenoids are another type of natural product reported to play a role in the prevention of
brain disorders [25,26]. These molecules are natural products distributed widely in plants, animals,
and microorganisms [27], and more than 750 carotenoids exist in nature. These compounds are
responsible for the yellow, orange, and red color in various plants and animals (birds, reptiles,
fish), and the color is indicative of the type of carotenoid [28–33]. Carotenoids are secondary
metabolites produced by enzymatic reactions, and these reactions generate different carotenoids
with biological importance [34,35]. Carotenoids play a variety of important functions in plants,
animals, and in the human brain. In plants, carotenoids are synthetized de novo where most are
enriched with a small quantity of its biosynthetic precursor [36]. The biosynthesis of carotenoids
is mediated by different enzymes and occurs in the plastids. They have functions such as light
harvesting in the photosynthetic membranes and protection of the photosynthetic apparatus against
photo-oxidation [34,37]. Carotenoids also act as precursors of the phytohormone abscisic acid
(ABA) [38] and are involved in the process of pollination as attractors of pollinators and seed dispersal
agents [34]. Some animals can synthetize carotenoids, but most depend on dietary intake. In
humans, these compounds have several therapeutic properties, including antioxidation, prevention of
neuro-inflammation, anti-cancer, anti-diabetes, prevention of cardiovascular disease, and potentially
the prevention and treatment of neurodegenerative disorders [39–43]. The antioxidant property of
carotenoids is the main therapeutic characteristic of this compound where the conjugate polyene chain
plays a crucial role in the reduction of free radicals [43–46]. This paper is focused on the chemistry of
carotenoids and, through molecular docking analysis, proposes plausible mechanisms by which they
may inhibit Aβ aggregation.
2. Chemistry of Carotenoid Compounds
Carotenoids belong to a class of terpenoid compounds with a characteristic conjugated polyene
chain composed of eight C5 isoprenoid units (Figure 1). The trans-carotenoid isomer is most
predominant in nature [47–51]. The large polyene chain enables light absorption in the range
of 450–550 nm of the visible spectrum [52]. The cis- and trans-carotenoid isomers have varying
melting points, with cis-isomers having a lower value than trans-carotenoids due to the decreased
tendency of cis-isomers to crystallize [28,53]. Meanwhile, cis-carotenoids can absorb light at a shorter
wavelength, with a lower absorption coefficient [54]. The soluble property of carotenoids is based on
their hydrophobic chemical structure, which makes them insoluble in water and dimethylsulfoxide,
but favors their solubility in organic solvents such as ethyl ether, chloroform, acetone, ethyl acetate,
and ethanol [55]. Most carotenoids are lipophilic with the ability to cross the blood-brain barrier [56].
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Carotenoids are considered “molecular rivets” since the width of this type of compound is the
same as that of the phospholipid bilayer which confers stability and rigidity to the phospholipid
membrane [57,58].
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epoxide, and keto groups [59,60]. Xanthophylls are formed from enzymatic reactions involving 
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(e.g., β-cryptoxanthin, zeaxanthin, and lutein), while epoxycarotenoids are xanthophylls with an 
epoxide group (e.g., antheraxanthin, violaxanthin, neoxanthin, β-carotene-5, 6-epoxide, β-carotene-
5, 6, 5’,6’-diepoxide, and β-Cryptoxanthin-5,6-epoxide) (Figure 2). Ketocarotenoids, such as 
astaxanthin, fucoxanthin, capsanthin, and capsorubin, are xanthophylls with a keto group [62].  
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Carotenoid synthesis can begin with the mechanism (1–4’) head-to-tail condensation of three 
isopentenyl diphosphates (IPP) and one dimethylallyl diphosphate (DMAPP) to produce the 
isoprenoid compound known as geranylgeranyl diphosphate (GGPP) [63]. The olefinic double bond 
of IPP nucleophilically attacks the carbocation produced through release of the allylic diphosphate 
group [63]. This reaction is catalyzed by GGPP synthase (GGPPS), and this enzyme has a mechanism 
of cyclic condensation: ionization-condensation-elimination [48,63]. GGPP is the precursor of 
different types of compounds such as carotenoids, plastoquinones, tocopherols, chlorophyll side 
chains, and phytohormones [63]. The head-to-head coupling of two GGPP catalyzed by phytoene 
synthase (PSY) produces a dimerized compound known as phytoene [34,64]. A phytoene compound 
is characterized by the presence of three conjugated double bonds in a chain.  
The production of carotenoids starts with phytoene synthesis, and this process is considered the 
rate-controlling reaction in the pathway [63]. The biosynthesis of phytoene is the first committed step 
in the desaturation process which leads to the formation of the conjugate double bond that is 
characteristic of carotenoids (Figure 2). The enzyme phytoene desaturase (PDS) introduces two 
conjugated double bonds into the long chain, forming a phytofluene compound. Then, the 
Figure 1. Numeration and biosynthesis of carotenoids: (a) Beta-carotene, capsanthin, and bixin are
examples of how carotenoids and apocarotenoid can be numerated; (b) the biosynthesis of carotenoids
starts with phytoenes that produce trans- and cis-carotenoids that can produce an epoxy carotenoid
and finally an apocarotenoid.
Carotenoids are classified into two groups, namely carotenes and xanthophylls, both of which
can be acyclic or cyclic compounds [59–61]. Carotenes have carbon and hydrogen atoms. The
most common acyclic carotene is lycopene, which is found in tomato, red-fleshed papaya, and
guava [55]. The most common cyclic carotene is β-carotene, which is found mainly in carrot, apricot,
and mango [55]. Other cyclic carotenes are β-zeacarotene, α-zeacarotene, γ-carotene, δ-carotene, and
α-carotene. Xanthophylls contain carbon, hydrogen, and oxygen atoms in their structure forming
hydroxyl, epoxide, and keto groups [59,60]. Xanthophylls are formed from enzymatic reactions
involving hydroxylases, epoxidases, or synthases. Carotenols are xanthophylls that possess a hydroxyl
group (e.g., β-cryptoxanthin, zeaxanthin, and lutein), while epoxycarotenoids are xanthophylls with an
epoxide group (e.g., antheraxanthin, violaxanthin, neoxanthin, β-carotene-5, 6-epoxide, β-carotene-5,
6, 5’,6’-diepoxide, and β-Cryptoxanthin-5,6-epoxide) (Figure 2). Ketocarotenoids, such as astaxanthin,
fucoxanthin, capsanthin, and capsorubin, are xanthophylls with a keto group [62].
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hydroxylation (3), epoxidation (4), and epoxide-furanoxide rearrangement (5).
3. Biosynthesis of Carotenoids
Carotenoid synthesis can begin with the mechanism (1–4’) head-to-tail condensation of three
isopentenyl diphosphates (IPP) and one dimethylallyl diphosphate (DMAPP) to produce the isoprenoid
compound known as geranylgeranyl diphosphate (GGPP) [63]. The olefinic double bond of IPP
nucleophilically attacks the carbocation produced through release of the allylic diphosphate group [63].
This reaction is catalyzed by GGPP synthase (GGPPS), and this enzyme has a mechanism of cyclic
condensation: ionization-condensation-elimination [48,63]. GGPP is the precursor of different
types of compounds such as carotenoids, plastoquinones, tocopherols, chlorophyll side chains, and
phytohormones [63]. The head-to-head coupling of two GGPP catalyzed by phytoene synthase (PSY)
produces a dimerized compound known as phytoene [34,64]. A phytoene compound is characterized
by the presence of three conjugated double bonds in a chain.
The production of carotenoids starts with phytoene synthesis, and this process is considered the
rate-controlling reaction in the pathway [63]. The biosynthesis of phytoene is the first committed step in
the desaturation process which leads to the formation of the conjugate double bond that is characteristic
of carotenoids (Figure 2). The enzyme phytoene desaturase (PDS) introduces two conjugated double
bonds into the long chain, forming a phytofluene compound. Then, the desaturation reaction gives rise
to another two conjugated double bonds, producing ζ-carotene. The poly-cis-carotenoid compound
generated in this biosynthetic process is converted into trans-carotenoid by carotene isomerase
(CRTISO) or ζ-carotene isomerase (ZISO). The neurosporene compound is biosynthesized by ζ-carotene
desaturase (ZDS), which introduces two conjugate double bonds into the chain [64]. This desaturase
enzyme continues the enzymatic process to form the lycopene compound by introducing two conjugate
double bonds. The cyclization of lycopene was proposed by Porter and Lincoln, who hypothesized that
cyclization can occur on one or both sides of the carotenoid to generate different type of compounds [63].
Two different rings, such as β- or ε-ionone rings, are generated from lycopene cyclization. Usually,
the main modification of the carotenoid occurs on the end, and only a few modifications occur in the
long chain of the carotenoid. The enzyme responsible for lycopene cyclization is lycopene cyclase
(LCY), which is found in plants and cyanobacteria. The type of carotenoid is determined by the
LCY subtype, namely β–ionone (LCYB) rings, ε-ionone (LCYE) rings, or bifunctional β/ε-ionone
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(LCYB/E) rings. An unsubstituted β-ionone ring is considered a source of vitamin A, a molecule
important for human health. In the presence of LCYB, lycopene is transformed into γ-carotene.
Meanwhile, lycopene in the presence of LCYE is transformed into δ-carotene. Both compounds
contain a six-member-ring at the end of the chain. LCYB can transform γ-carotene into β-carotene,
a compound with two six-member rings at the end of the chain. A similar transformation occurs
with δ-carotene, which is transformed into α-carotene. The addition of hydroxyl and keto groups to
carotenoids can be achieved through two different classes of enzymes, ferredoxin-dependent nonheme
diiron enzymes (HYD) and enzymes to belonging to the cytochrome P450 family [63]. The first is a
type of β-hydroxylase that is responsible for β-cryptoxanthin and zeaxanthin formation. Cytochrome
P450 has a novel ε-hydroxylase that is responsible for hydroxylation of the ε-ionone ring to form
zeinoxanthin. The enzyme capsanthin-capsorubin synthase converts epoxycarotenoids into κ-cyclic
carotenoids such as capsanthin and capsorubin [65]. Epoxidation reactions also occur in carotenoids
through epoxidases such as zeaxanthin epoxidase (ZEP), which is responsible for antheraxanthin and
violaxanthin formation.
Apocarotenoids have a structure similar to carotenoids but without C40 atoms (Figure 3). An
apocarotenoid is considered a product of oxidative cleavage of carotenoids, and the most well-known
apocarotenoids are Apo-12’-capsorubinal and bixin [66,67].
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The five important reactions involved in carotenoid biosynthesis are desaturation (1), cyclization
(2), hydroxylation (3), epoxidation (4), and epoxide-furanoxide rearrangement (5) (Figure 2) [55]. The
desaturation reaction (Figure 4) is essential for the formation of conjugate double bonds in the chain of
the carotenoid. Formation of the lycopene compound starts with desaturation of phytoene, which
contains three conjugated double bonds, and then proceeds with the formation of phytofluene, which
contains five conjugated double bonds, ζ-carotene, which possesses seven conjugated double bonds,
neurosporene with nine conjugated double bonds, and finally lycopene, which contains 11 conjugated
double bonds [55,68]. Because the flavin cofactor can accept one or two electrons, four mechanisms
have been reported to demonstrate how phytoene desaturation proceeds, namely through single
electron transfer, the formation of hydride from substrate, transfer to flavin adenine dinucleotide (FAD),
hydrogen atom transfer, and nucleophilic attack [68]. The cyclization reaction (Figure 4) is important
in ring formation of the carotenoid. Lycopene is the important carotenoid which starts the cyclization
process [69]. The reaction mechanism consists of attacking the alkene in the C2 position of the lycopene
to generate an acid-producing carbocation in the lycopene, which is stabilized by deprotonation of
hydrogen in C4, C18, or C6 to yield a β-end-group, γ-end-group, or ε- end-group (Figure 3). Two types
of rings can be formed, such as the β-ionone ring, at the end-group of both sides (e.g., β-carotene) [69].
The ε-ring can be formed at one side of the compound such as in α-carotene [69].
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The hydroxylation reaction (Figure 5) is quite common in β- or ε-ionone rings in carotenoids. The
addition of this group to the ring causes a loss in vitamin A properties [63]. Xanthophyll functions
in preventing damage caused by photo-oxidation. The hydroxylation reaction is carried out by two
classes of enzymes, namely ferredoxin-dependent nonheme diiron enzymes (HYD) and enzymes of the
cytochrome P450 family [70,71]. A plausible mechanism of carotenoid hydroxylation by HYD has been
proposed based on studies of alkane mono-oxygenase and l-p-amino phenylalanine hydroxylase, where
the first step consists of binding of one oxygen molecule to an iron cluster to form the peroxodiferric
intermediate. This step is followed by hydrogen abstraction of the carotenoid by a potent oxidant (Q),
resulting in the formation of a carotenoid radical that interacts with the iron complex to hydroxylate
the carotenoid [70–72]. The epoxidation reaction (Figure 5) of carotenoids can lead to structural
modification of the β-ionone ring at the 5,6-position (e.g., antheraxanthin is epoxidized at one site by
zeaxanthin epoxidase (ZEP) [38,69]. However, the epoxidation reaction is a reversible reaction in the
presence of violaxanthin de-epoxidase (VDE), forming the xanthophyll cycle which plays an important
role in the regulation of photosynthetic energy conversion [73]. In the epoxide-furanoide rearrangement
reaction (Figure 5), the epoxide carotenoid can undergo epoxide-furanoxide rearrangement in the
presence of acid to produce a different type of end-group. The type of end-group is determined by the
carbocation position and hydrogen abstraction by a base (B-), such as the k-end-group, γ-end-group,
or ε-end-group, which is produced when the carbocation is in the C5 position. Meanwhile, the
epoxide-furanoxy rearrangement known as 5,8-epoxide carotenoid occurs when the carbocation is in
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the C6 position [69]. Capsanthin-capsorubin synthase (CCS) is the enzyme responsible for k-end-group
formation, where pinacol rearrangement occurs to form a new family of carotenoids [67].
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4. Types of Carotenoid Derivatives
The synthesis of carotenoid derivatives with hydrophilic properties are a good alternative for
incorporating this type of molecule with multiple therapeutic properties in aqueous medium [74,75].
Carotenoids have an important nutritional value since most of them are a source of vitamin A,
antioxidant molecules with anti-carcinogenic properties, and the ability to prevent cardiovascular
disease [41,45]. Synthesizing hydrophilic carotenoid derivatives is important due to their use as
therapeutic molecules that improve the biological activity of carotenoids. Another reason to produce
synthetic carotenoid derivatives is their increased water solubility. This property allows carotenoids
to be widely used in the food industry as natural dyes. Several types of carotenoid derivatives have
been synthetized, including reduced carotenoids, carotenoid epoxides, carotenoid esters, carotenoid
glycosides, and PEGylated carotenoids (Figure 6) [75]. Below, we briefly describe the types of carotenoid
derivatives synthesized with hydrophilic properties.
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reagent NaBH4 in EtOH or EtOH/benzene is used to reduce the keto group of the carotenoid to generate
two s er oisomeric alcohols (Figure 6) [76]. Carotenoid epoxi es: Carotenoids are a source of vitamin
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epoxidation is prepared using monoperoxyphthalic ac d to produc two types of poxides that can be
separated through a chiral column (Figure 6) [77,78]. Carotenoid esters: Carotenoids, with the exception
of bixin and cro in, are poor water-soluble molecule . The synthesis of carotenoid d rivatives with
water-soluble charact ristics enables the therapeutic properties of this type of c mpound in aqueous
olutions ( .g., Cardax) [75,79]. Esterific ti n f carotenoids is most frequently performe usi g
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4-dimethylaminopyridine (DMAP) in dichloromethane (CH2Cl2) [39,80,81]. Meanwhile, phosphate
is produced using lutein with dibenzyl phosphoroiodidate in CH2Cl2 [82]. Finally, preparation of
the astaxanthin-amino acid conjugate can be achieved using Nαε-bis-(tert-butoxycarbonyl)-L-Lysine
(BocLys(Boc)OH) with DMAP in CH2Cl2 and 1,3-diisopropylcarbodiimide (DIC), [83]. These types of
carotenoid derivatives have been demonstrated to exhibit increased solubility in polar solvents when
they are converted to sodium salt [82].
Carotenoid glycosides: This type of carotenoid derivative is found in nature in some microorganisms
that are characterized by their resistance to heat, specifically the Thermus species. Thus, this type of
compound is known as a thermoxanthin [75]. The presence of glycoside makes it more water soluble
and amphiphilic. Yamano, et al. achieved synthesis of thermocryptoxanthin and thermozeaxanthin [84].
Glucosidation can be performed by combining glucosyl bromide with silver triflate (AgOTf) in some
cases in the presence of N,N,N’,N’-tetramethylurea as a proton acceptor (Figure 6) [84]. PEGylated
carotenoids: A polyethyleneglycol (PEG) conjugate is widely used for its pharmacokinetic properties
and solubility in aqueous solution [39,74]. This type of carotenoid derivative is synthetized by
coupling succinate with polyethylene glycols using dicyclohexylcarbodiimide (DCC) with DMAP in
CH2Cl2 [81,85]. Another type of carotenoid derivative is produced by the azide-alkyne click reaction,
which is well known for increasing water solubility (Figure 6) [75,86].
5. Neuroprotection by Carotenoids through Modulation of the App Pathway
Aβ peptide is formed by cleavage of amyloid precursor protein (APP), which is catabolized by
secretases (α, β, and γ secretase), to form non-amyloidal and/or amyloidal products [87–89]. APP is a
multidomain glycoprotein with signal peptide regions located at residues 1–17, two copper-binding
sites at amino acids (aa) 124–189, and an E2 domain 376 where chromosome 21 produces eight isoforms
of APP (695–770). The major isoform is APP 695. When the N-terminal region of APP is cleaved by
β-secretase, secreted APP fragment beta (sAPPβ) is formed and γ-secretase transforms C-terminal
fragment beta (CTFβ) in Aβ at the copper-binding site [90]. The non-amyloidogenic α-secretase
belongs to the family of zinc metalloproteinases that cleaves APP at Lys687. Amyloidogenic aspartyl
protease β-secretase cleaves at Met671, while γ-secretase cleaves at Val711 and Ala713 to form Aβ40
and Aβ42, respectively [90–93].
Several studies have demonstrated that carotenoids can inhibit Aβ aggregation [45,56,94–96].
Carotenoids such as lutein, lycopene, astaxanthin, fucoxanthin, cryptocapsin, and the apocarotenoid
crocin have been demonstrated to inhibit Aβ42 aggregation (Figure 7). Lutein, a hydroxylated carotenoid
present in apricot extract, exhibits a strong inhibition of Aβ42 fibril formation [56]. Katayama, et
al. compared lutein with zeaxanthin, β-cryptoxanthin, β-carotene, and α-carotene, and found that
lutein has the highest activity. The authors hypothesized that the number of hydroxyl groups plays
an important role in the inhibition of Aβ aggregation [56]. Lycopene, an acyclic carotene found in
tomatoes with a highly conjugated structure, has been shown to exhibit multiple benefits including
inhibition of Aβ42 formation [94–96]. Wang, et al. found that lycopene can reduce Aβ aggregation
and inhibit the inflammatory response by suppressing microglia activation and increasing antioxidant
enzyme activities [94]. Crocin, an unusual polar apocarotenoid found in Crocus sativa stigma, possesses
an inhibitory activity similar to Aβ [43,97]. Papandreou, et al. found that trans-crocin-4 is the main
apocarotenoid present in the perennial herb of the Iridaceous family [43]. Astaxanthin, a ketocarotenoid
found in crustacean shells, is also considered to be a highly antioxidant molecule [62,98]. Lee, et
al. found that astaxanthin can inhibit nitric oxide production in vitro and in vivo [98]. Fucoxanthin,
an allene carotenoid found in marine microorganisms, have multiple therapeutic properties such as
reduction of oxidative stress, decreased inflammation, decreased obesity effect, and inhibition of Aβ
assembly [99,100]. Xiang, et al. demonstrated that fucoxanthin could inhibit Aβ assembly and that this
inhibition is reinforced by hydrophobic interaction between this carotenoid and the Aβ peptide [100].
A recent study showed that fucoxanthin could inhibit β-secretase by hydrogen bonding with this
enzyme [101]. Inhibition of this enzyme is another neuroprotective activity of carotenoids, and occurs
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by blocking the amyloidogenic pathway via inhibition of the initiation of APP cleavage to produce
Aβ peptide [101]. Cryptocapsin is a ketocarotenoid with a non-conventional keto-kappa group found
in Pouteria sapota [102,103]. We found that this carotenoid could potently inhibit Aβ42 aggregation
whereas cryptocapsin-5,6-epoxide, which is found in the same fruit, exhibited only a minor activity.
Both carotenoids were compared with zeaxanthin, and the data demonstrated that cryptocapsin and
zeaxanthin showed potent inhibition of Aβ42 aggregation [25]. These results led us to conclude that
hydroxyl and keto groups increase their activity while an epoxide group reduces it [25].
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Carotenoids are fascinating molecules that exhibit high antioxidant potential [104–106]. Lycopene,
lutein, fucoxanthin, astaxanthin, cryptocapsin, and crocin are the most effective carotenoids in inhibiting
Aβ aggregation. They have different structural characteristics, such as cyclic and acyclic structures,
where the presence or absence of hydroxyl, epoxide, allenic, and keto groups is observed.
Our question is, when the process of aggregation begins, how does the carotenoid inhibit Aβ
aggregation? We observed that a long chain of conjugated double bonds is present in these carotenoids
(Figure 7), and that this polyene chain is responsible for their antioxidant activity by stabilization of
radical species [52,107]. Nevertheless, how does the carotenoid inhibit Aβ aggregation? We observed
that these carotenoids are oriented perpendicular to the Aβ peptide. This leads us to infer that the
long polyene chain may block stacking of the peptide. Most likely the carotenoid conformation can
be reinforced by the hydrogen bonding interactions or pi-pi stacking interactions that occur between
the polar residues of the Aβ peptide, such as Glu22, Asp23, and Gly25, and the functional groups
of the carotenoid (e.g., mainly the hydroxyl groups) [25]. Based on this observation, we conducted
molecular docking analysis using five carotenoids with different structures and evaluated them against
Aβ peptide aggregation.
6. Molecular Docking Analysis of Carotenoid and Apocarotenoid against Aβ Aggregation
Cryptocapsin, lutein, fucoxanthin, astaxanthin, and bixin were the carotenoids selected for
molecular docking analysis. Because cryptocapsin was the most active in our experimental results,
this compound was selected as our standard. Our objective was to perform structural analysis of
carotenoids to evaluate how they prevent Aβ aggregation. Despite the fact that a vast number of
carotenoids exist in nature, these five were selected based on their structural differences to examine
whether these variations play a crucial role in Aβ aggregation.
We u d a computational structure-based drug design and ev luated the possible interaction
modes between differ nt forms of Aβ fibrillar species, includi g Aβ42 and Aβ40, with car tenoid
ligands like astaxanthin, bixin, cryptocapsin, fucoxanthin, and lutein retrieved from the PubChem
database [108]. The molecular docking experiments were performed using CDOCKER, a docking
protocol developed by Discovery Studio 3.5 (Accelrys, San Diego, CA, USA). The three-dimensional
(3D) solution and solid state NMR structures of U-shaped pentamer Aβ17–42 Protein Data Bank (PDB)
identification (ID) were: 2BEG S-shaped Model Aβ11–42; PDB ID: 2MXU Disease-Relevant structure of
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Aβ42; PDB ID: 2NAO and Aβ40 derived from the brain of a patient suffering from AD; and PDB ID:
2M4J obtained from the RCSB PDB [109] (Figure 7).
The ligands and retrieved target PDB Aβ fibril NMR structures were minimized by using the
conjugate gradient protocol and employing the CHARMm force field with Max Steps-2000 implemented
in Discovery Studio 3.5 software (Accelrys, San Diego, USA).
The initial step was carried out by preparing different forms of Aβ fibrils and identifying the
binding sites by using the Define and Edit binding site tool. The binding sites found are shown in
Figure 8 as a set of points. Docking studies were carried out using the CDOCKER protocol under the
Receptor-Ligand Interaction tools in Discovery Studio 3.5. CDOCKER is a powerful CHARMm-based
docking method that has been shown to generate highly accurate docked poses [110].
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Figure 8. Probable receptor binding sites and alternative binding regions across different Aβ fibrils
where ligand binding interactions can occur. Red dots correspond to the amino acid in the binding site.
The carotenoid ligands astaxanthin, bixin, cryptocapsin, fucoxanthin, and lutein (Figure 9) were
docked onto the different forms of Aβ42 and Aβ40 fibrils. First, the Aβ fibril was held in a rigid
conformation and the carotenoid ligands were allowed to flex during the refinement. Docking runs
were adjusted t the 10–100 best outputs for valuation of bind pos accuracy. Co sequently,
diverse poses are generated which adopted the random rigid bo y rotation and simulat d a nealing.
Ligan s displayed efficient docking with the generation of 10 conformers each. For each carotenoid
ligand, the top 10 ligand binding poses were ranked according to their CDOCKER energies, which
were calculated based upon the internal ligand strain energy and receptor-ligand interaction energy.
The CDOCKER interaction signifies the energy of the non-bonded interaction that exists between the
protein and ligand. It must be noted that, in both cases, greater CDOCKER energy and CDOCKER
interaction energy values imply more favorable binding between the Aβ fibril and the ligand and
therefore the best shape complementarity. The simulated docked complexes were studied based on the
lowest binding affinity values (kcal/mol) and bonding interaction patterns (hydrogen, hydrophobic,
and electrostatic). All ligand-protein interactions that exhibited stronger binding affinity and energies
relative to individual targets are computed.
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fucoxanthin, both f them are carotenoids with no - itamin A, and finally, Bixin, apocatenoid
without pro-vitamin A.
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It is interesting to understand that different types of structural polymorphism in the Aβ fibrils
occur from the same polypeptide sequence in AD. These differences lead to variations in protofilament
number, arrangement, and polypeptide conformations to numerous dissimilar patterns of inter-
or intra-residue interactions. However, the most prevalent forms of Aβ peptides are Aβ40 and
Aβ42 aa residues, with Aβ42 being the more toxic form over Aβ40. The higher toxicity of Aβ42
chains may be explained by their ability to adopt three-stranded S-shaped antiparallel β-strands as a
cylindrical barrel/pore-like structure when assembling as fibrils. In contrast, U-shaped configurations
can only be observed for Aβ40 peptides. Consistent with this, the patient-derived fibril structure
of Aβ40 chains possesses a three-fold symmetry which cannot take an S-shaped form but rather a
U-shaped configuration that differs from other fibril polymorphs, which are more significant than
other polymorphs for the pathology of AD. Hence, the present computational study is also intended to
understand and appreciate the binding modes of carotenoids and their effect on fiber stability and fiber
toxicity with four different forms of Aβ. The initial outcomes of the binding site analysis revealed that
all four Aβmodels exhibited interesting known binding sites and different small and large binding
regions with uninformed size and depth across the Aβ fibril surface, where small molecule/large ligand
binding interactions can occur. Docking studies of astaxanthin, bixin, cryptocapsin, fucoxanthin, and
lutein binding with the selected model showed promising interactions of the ligands with each docked
fibril. The ligand-protein complex was evaluated for hydrogen bond interactions and CDOCKER
interaction (kcal/mol−1) energies.
Evaluating the interactions revealed that all the ligands exhibited strong interactions with residues
such as Glu22, Val24, Gly25, Asp23, Ser26, Lys28, and Leu34, which participate in hydrogen bond
formation (Table 1). Moreover, Ala21, Ile32, Gly33, Gly38, and Val39 participated through van der Waals
interactions. Lutein showed the lowest CDOCKER energy (97.6659 kcal·mol−1), signifying greater
interaction across 2BEG Aβ42 fibrils. Irrespective of the binding energies projected for the ligands, all
exhibited a similar binding mode pattern. Based on the data presented in Table 1, carotenoid-mediated
inhibition of Aβ aggregation can be ranked as lutein > bixin > cryptocapsin > astaxanthin > fucoxanthin.
Table 1. Interactions of ligands with the U-shaped pentamer Aβ17–42 using PDB ID: 2BEG.
Ligands
Highest
-CDOCKER
Energy (kcal/mol)
Highest
-CDOCKER
Interaction Energy
(kcal/mol)
Amino Acid Residues
Interacting with Aβ
Chains
Common Residues
Interacting Across
all Ligands
Astaxanthin −83.0351 −17.3682 Gly38, Val39 Ala21, Glu22 *,
Val24 *, Gly25 *,
Asp23 #,
Ser26 #, Lys28 #,
Ile32, Gly33;
Leu34 *, Gly38,
Val39
Bixin −85.044 −127.336 Glu22 *
Cryptocapsin −83.6518 −14.4395 Leu34 *, Ile32, Gly33,Gly33
Fucoxanthin −69.4873 −39.3977 Asp23 #, Glu22, Ala21
Lutein −97.6659 −20.8785
Asp23 *, Val24 *,#,
Gly25 *,#, Lys28 #,
Ser26 #
* Denotes main chain interactions and # specifies side chain interactions.
Similarly, this analysis revealed important interactions between carotenoids and 2MXU Aβ11–42
(Table 2). All of these residues have been shown to interact with ligands via hydrogen bond
formation while the remaining amino acids in the pocket display van der Waals interactions. Lutein
(−60.6453 kcal/mol) exhibited the lowest CDOCKER energy. Regardless of their binding energies, all of
the ligands exhibited a similar binding mode pattern with shared interacting residues such as Val12,
His14, Ile32, Gly33, and Leu34. Based on the data in Table 2, carotenoid-mediated inhibition of Aβ
aggregation can be ranked as lutein > cryptocapsin > fucoxanthin > astaxanthin > bixin.
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Table 2. Interactions of ligands with the S-shaped model structure of Aβ11–42 using PDB ID: 2MXU.
Ligands
Highest
-CDOCKER
Energy (kcal/mol)
Highest
-CDOCKER
Interaction Energy
(kcal/mol)
Amino Acid
Residues
Interacting with
Aβ Chains
Common
Residues
Interacting Across
all Ligands
Astaxanthin −36.1994 −60.0733 Val2, His14
Val2, His14
Ile32, Gly33,
Leu34
Bixin 10.2499 −45.5219 Leu34, Gly33
Cryptocapsin −44.9219 −60.0403 Gly33, Ile32, Gly33
Fucoxanthin −40.2796 −60.6453 Leu34, His14
Lutein −60.6453 −50.7407 His14
Furthermore, the docking outcomes of the 2NAO-Disease-Relevant structure of Aβ42 with
carotenoids are shown in Table 3. These data reveal that all of the ligands form stable hydrogen bonds
and van der Waals interactions. The other amino acid residues across the ligands participated via
van der Waals interaction. However, cryptocapsin (−84.343 kcal/mol) and lutein (−88.1515 kcal/mol)
exhibited the lowest CDOCKER energy. While all ligands share common interacting residues like
Ser8, Glu11, Lys16 across the binding site of 2NAO. Based on the data in Table 3, carotenoid-mediated
inhibition of Aβ aggregation can be ranked as lutein > cryptocapsin > astaxanthin > fucoxanthin
> bixin.
Table 3. Interactions of ligands with the structures of Aβ (1–42) using PDB ID: 2NAO-Disease-Relevant.
Ligands
Highest
-CDOCKER
Energy (kcal/mol)
Highest
-CDOCKER
Interaction Energy
(kcal/mol)
Amino Acid Residues
Interacting with
Aβ Chains
Common
Residues
Interacting Across
all Ligands
Astaxanthin −76.0481 −29.5232 Ser8, Glu11, Gly9 Tyr10
Ser8,
Glu11,
Lys16
Bixin −74.169 −104.431 Glu22, Glu11
Cryptocapsin −84.3430 −33.051 Lys16, Glu18
Fucoxanthin −75.0944 −37.7015 Lys16, His13
Lutein −88.1515 −30.5548 Ser8
Carotenoids also interact with 2M4J-Aβ40 derived from the brain of a patient suffering from AD.
As shown in Table 4, all of the ligands exhibited strong interactions with residues such as Glu28 and
Gly37 through hydrogen bonding. The other amino acids participated by van der Waals interactions.
Cryptocapsin (−101.782 kcal/mol) and lutein (−110.897 kcal/mol) exhibited the lowest CDOCKER
energy. Based on the data in Table 4, carotenoid-mediated inhibition of Aβ aggregation can be ranked
lutein > cryptocapsin > fucoxanthin > astaxanthin > bixin.
Table 4. Interactions of ligands with the structures of Aβ (1–40) derived from brain of a patient with
AD using PDB ID: 2M4J.
Ligands Highest -CDOCKEREnergy (kcal/mol)
Highest -CDOCKER
Interaction Energy
(kcal/mol)
Amino Acid Residues
Interacting with
amyloid-β chains
Astaxanthin −82.9702 −18.1365 -
Bixin −22.6447 −16.4999 Lys28
Cryptocapsin −101.782 −14.0123 Gly37
Fucoxanthin −89.3804 −18.9031 Gly37
Lutein −110.897 −16.1726 Gly37
A comparison of the different highest CDOCKER energy values allowed us to propose a
hypothetical percentage of inhibition of Aβ aggregation by these five carotenoids (Figure 9). We
observed that lutein was the most powerful carotenoid against Aβ aggregation followed by cryptocapsin.
Astaxanthin and fucoxanthin showed moderate inhibition of Aβ aggregation. However, bixin, an
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apocarotenoid, displayed the lowest inhibition of Aβ aggregation. Therefore, we propose that
carotenoids have greater potential to inhibit Aβ aggregation than apocarotenoids.
According to published literature, ligands which bind to the Aβ16–20 region of Aβ42 are capable
of disrupting Aβ fibril formation. Likewise, studies have revealed that amino acid residues 16 to 20 in
Aβ16–20 are required for the self-association of Aβ peptides into Aβ fibrils. Aβ16–20 forms an antiparallel
β-sheet structure through binding to the homologous regions of amino acids 17–21 or 18–22 [111,112].
Similarly, it has been shown that Aβ16–20 deletion, as the most important nucleation site, inhibits
formation of the Aβ fibril [113]. Therefore, our docking analysis clearly indicates that ligands strongly
interact in close contact with the 20–28 regions and hydrogen bonding at the Asp23-Lys28 salt bridge,
resulting in disruption of the stability of the salt bridge and the oligomer structure as well as sheet
breaking activity. Moreover, C-terminal residues such as Gly33, Met35, Val36, and Gly37 indicate that
these ligands may disaggregate Aβ fibrils through their binding [111,113]. The data in Table 5 suggest
that carotenoids and apocarotenoids can disrupt Aβ aggregation and the disaggregation pathway.
Lutein can potentially inhibit oligomer formation due to interactions with residues 20–28 of the Aβ
peptide, which are essential for oligomerization. Cryptocapsin has the potential to inhibit Aβ fibril
formation due to interaction with residues 16–20. This carotenoid can also disaggregate Aβ fibrils
through interaction with residues 33–37. Fucoxanthin is different from these carotenoids due to its
potential to inhibit Aβ fibril formation, Aβ disaggregation, and oligomerization through interaction
with residues 16–20, 24–28, and 33–37. Astaxanthin interacts with the Aβ peptide at amino acids 8–14,
which are crucial for aggregation through interactions with metals such as Zn (II) and Cu (II) or Fe
(II) and Al (III). This is a crucial metal-binding region [114]. However, we can hypothesize that its
inhibition is based on disruption of hydrogen bond formation with residues 8–14 where this carotenoid
has strong interactions with the polar residues of the Aβ peptide. Bixin, an apocarotenoid, has less
contact with the Aβ peptide than carotenoids because it consists of half the number of carbons and
possesses a cis conformation that reduces contact with the Aβ peptide. However, this apocarotenoid
can interact with polar amino acids such as Glu11 and Glu22, Lys28, Gly33, and Leu34, indicating a
potential for disrupting hydrogen bond formation with the Aβ peptide.
Table 5. Summary of interactions of the five compounds with the Aβ (1–42) sequence. Color code:
astaxanthin (red), bixin (blue), cryptocapsin (purple), fucoxanthin (green), and lutein (yellow).
Ligands 8 9 10 11 12 13 14 16 18 21 22 23 24 25 26 28 32 33 34 37 38 39
S G Y E V H H K V A E D V G S K I G L G G V
Astaxanthin
Bixin
Cryptocapsin
Fucoxanthin
Lutein
These results have allowed us to evaluate the inhibitory potential that carotenoids and
apocarotenoids may possess. These data provide hints of their aggregation and disaggregation
potential against Aβ formation. Some carotenoids can inhibit Aβ aggregation by interacting with
residues in the regions of 8–14 and 16–20, which are essential for this procedure. On the other hand,
there are carotenoids that can disaggregate Aβ fibrils by interacting with the 33–37 regions that are
required for the fibrillation process. Nevertheless, there are carotenoids that can inhibit amino acids
23–28, which are essential for oligomerization. We also observed that there are carotenoids that may
inhibit Aβ fibril aggregation and disaggregation.
Thus, we propose a plausible mechanism by which carotenoids inhibit Aβ aggregation and
disaggregation. Our mechanism starts a proposal that the long chain of conjugated double bonds,
characteristic of carotenoids, has a dual function. First, this polyene chain confers an antioxidant
property to carotenoids by stabilizing radical species. Second, based on the planar structure of
the polyene chain due to trans-configuration that is longer than the Aβ peptide, a perpendicular
orientation may block self-aggregation of the peptide. The conformation of the carotenoid is reinforced
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by chemical interactions between the functional group of the carotenoid with polar residues of the
Aβ peptide. For instance, all four carotenoids examined in this study share a similar polyene chain
structure with trans-configuration. However, the apocarotenoid (bixin) has a short polyene chain with
a cis-configuration. The carotenoid with a trans-configuration may have more potential to inhibit Aβ
aggregation than a molecule with a cis-configuration. Another important difference that was observed
is related to the quantity and positioning of hydroxyl groups within the molecule. For example, lutein,
the most powerful carotenoid against Aβ aggregation, has two hydroxyl groups in the two β–ionone
ring, specifically in the C3 position. Cryptocapsin possesses one hydroxyl group in the 6-oxo-kappa
end-group, specifically in the C3 position. Astaxanthin has two hydroxyl groups in the C3 position;
however, this carotenoid is predicted to have lower potential for inhibiting Aβ aggregation than lutein.
Therefore, it is possible that the keto-kappa groups and configuration of hydroxyl groups play a role in
the inhibition of Aβ activity. Fucoxanthin has two hydroxyl groups but in different positions, as well
as an epoxide group and an allene group that could influence the activity. The apocarotenoid bixin
demonstrated the importance of the double-bond chain length in Aβ inhibition. These preliminary
results allow us to propose a structure-activity relationship (SAR) where the double-bond chain is
crucial for contact with the Aβ peptide. However, the hydroxyl group in the hydrogen bond interaction,
along with their position and configuration in the molecule, is also important. Finally, the presence of
epoxide, allene, and keto groups in the molecule may also affect Aβ inhibition.
In the published literature, little data exists showing the neuroprotective activity of carotenoids.
While studies of these compounds have demonstrated their role in inhibiting the aggregation or
disaggregation of Aβ fibrils, the underlying mechanism remains unknown. Thus, our proposed
mechanism is based on two requirements: 1) blocking self-aggregation of the Aβ peptide by the length
and configuration of the compound avoids self-assembly; and 2) the quantity and position of the
hydroxyl groups are essential for interacting with the Aβ peptide/fibril through hydrogen bonding.
Figure 10 is a schematic detailing the mechanism by which carotenoids can inhibit Aβ aggregation
and disaggregation.
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Figure 10. The hypothetical model to understand the role of carotenoids in the inhibition of Aβ42
formation. β- and γ-secretases are the two enzymes that cleavage the amyloid precursor protein (APP)
to form Aβ peptide. The aggregation of this peptide pass to dimer follows to oligomer until Aβ fibril.
Carotenoids may potentially inhibit the APP pathway where carotenoids have been demonstrated to
inhibit Aβ dimer, also oligomer, and also the disaggregation of Aβ fibril. Color code: Aβ (yellow),
carotenoid (red), β-secretase (brown) and γ-secretase (green).
7. Aβ Aggregation and DNA Damage
While we focused on the neuroprotective activity of carotenoids especially for their role of
inhibition of Aβ aggregation, this property is also important due to its potential effect on Aβmediated
genome instability. Previous studies have demonstrated a relationship between Aβ aggregation and
DNA damage [11]. This raised the question whether the carotenoid compounds that inhibit Aβ
aggregation also inhibit or prevent the DNA damage [11]. Indeed, studies have found that carotenoids
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can prevent the DNA damage [115–117]. This activity can be related to the type of carotenoid: the
pro-vitamin A and non-vitamin A groups of carotenoids. The pro-vitamin A can be found in β-carotene
and β-cryptoxanthin and lycopene, lutein, and astaxanthin possess the non-vitamin A property.
Lutein can prevent the DNA damage when they exposed lutein to ultraviolet radiation using human
neuroblastoma and rat trachea epithelial cells [118,119]. Future studies should investigate the protective
effect of carotenoids on genome integrity, which could be important for both neurodegeneration and
cancer prevention.
8. Conclusions and New Directions in Research
Carotenoids are natural products with a high therapeutic potential against neurodegenerative
diseases, especially AD. For this reason, it is important to further explore comprehensively, mechanistic
basis of carotenoids as a new source of therapeutic compounds in the fight against this devastating
neurodegenerative disease. In this paper, we discussed the diversity of carotenoids found in nature and
their high potential as therapeutic molecules involved in preventing multi-faceted toxic pathways of
Aβ. Carotenoids are widely distributed in nature and exist in a variety of different types. However, only
a few carotenoids have been characterized for their neuroprotective activity. We consider carotenoids
as powerful natural compounds with nutraceutical and antioxidant properties that are critical in the
fight against AD. Furthermore, most carotenoids can cross the blood-brain barrier. Future studies are
in progress to evaluate the neuroprotective activity of carotenoids and their derivatives.
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